United States · 
Who invested in RedShift BioAnalytics?
RedShift BioAnalytics's investors include Technology Venture Partners and Waters Corporation.
United States · Series C startup
Who invested in RedShift BioAnalytics
Funding summaryUpdated 26 Oct 2026
$11Mraised across 1 round since 2017, from 1 source
- Latest round
- Series C, $11MMar 2017
- Investors
- 2
The rounds
- Mar 2017Series C$11M
Reported by FinSMEsSEC filing: $11M sold, first sale Feb 2017
Founders and team
From RedShift BioAnalytics's own website: 6 on the team.
- Tom O'LenicChief Executive Officer
- Dennis MerrillChief Operating Officer
- Eugene MaChief Technology Officer
- Sebastian ArevaloChief Commercial Officer
- Sean VealeVP of Software
- Bryson HollimonTechnology Venture Partners (Chairman)
Everyone who backed them
Technology Venture PartnersGrowth equity1round
Missing a round, or an investor who was in one? Tell us.
Also claim to have backed them
This firm lists RedShift BioAnalytics as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.
Quick answers about RedShift BioAnalytics
How much has RedShift BioAnalytics raised?
RedShift BioAnalytics has raised $11M across 1 round since 2017.
When did RedShift BioAnalytics last raise?
RedShift BioAnalytics's most recent round was a Series C of $11M in Mar 2017.
What was RedShift BioAnalytics's biggest round?
Its most recent round, $11M in Mar 2017, is also its largest on record.
Who backed RedShift BioAnalytics first?
RedShift BioAnalytics's first round on record, in Mar 2017, was backed by Technology Venture Partners and Waters Corporation.
What stage is RedShift BioAnalytics at?
RedShift BioAnalytics's latest named round is a Series C, in Mar 2017.
Where is RedShift BioAnalytics based?
RedShift BioAnalytics is based in the United States.
Companies like RedShift BioAnalytics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.